Novo Nordisk GLP-1 liraglutide may slow Alzheimer’s progression
A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, …
Biogen Inc
Eisai Biogen Alzheimer’s drug Leqembi shows benefits over three years
The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. Hannah Yoon | The Washington Post | Getty Images …
GEHC gives reasons to look beyond temporary China woes and shares reverse higher
GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it …
Biogen (BIIB) earnings Q2 2024
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Thursday reported second-quarter earnings and …
Eli Lilly (LLY) says it can overcome high-quality problem of too much demand
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly …
Biogen (BIIB) earnings Q1 2024
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported first-quarter profit that …
Analysts cut their price targets on these 10 stocks ahead of earnings
Analysts have lowered their expectations on several global stocks this week by cutting their price targets. The list of stocks includes auto stocks Tesla , Rivian and Aptiv , pharmaceutical …
Eli Lilly Alzheimer’s drug FDA approval delayed
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the …
Alzheimerâs drug Leqembi launch, Apple Vision Pro nausea
Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. …
Pharma, ride-share providers among most overbought S&P 500 stocks
A group of well-known stocks including some industry titans could be in for a correction after getting snatched up during this week’s choppy trading. The S & P 500 and …